The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population

Anurag Verma(Translational Therapeutics (United States)), Scott M. Damrauer(Translational Therapeutics (United States)), Nawar Naseer(Translational Therapeutics (United States)), JoEllen Weaver(Translational Therapeutics (United States)), Colleen Morse Kripke(Translational Therapeutics (United States)), Lindsay Guare(University of Pennsylvania), Giorgio Sirugo(Translational Therapeutics (United States)), Rachel L. Kember(University of Pennsylvania), Theodore G. Drivas(University of Pennsylvania), Scott Dudek(University of Pennsylvania), Yuki Bradford(University of Pennsylvania), Anastasia Lucas(University of Pennsylvania), Renae Judy(University of Pennsylvania), Shefali S. Verma(University of Pennsylvania), Emma A. Meagher(Translational Therapeutics (United States)), Katherine L. Nathanson(University of Pennsylvania), Michael D. Feldman(University of Pennsylvania), Marylyn D. Ritchie(University of Pennsylvania), Daniel J. Rader(Translational Therapeutics (United States)), For The Penn Medicine BioBank
Journal of Personalized Medicine
November 29, 2022
Cited by 145Open Access
Full Text

Abstract

The Penn Medicine BioBank (PMBB) is an electronic health record (EHR)-linked biobank at the University of Pennsylvania (Penn Medicine). A large variety of health-related information, ranging from diagnosis codes to laboratory measurements, imaging data and lifestyle information, is integrated with genomic and biomarker data in the PMBB to facilitate discoveries and translational science. To date, 174,712 participants have been enrolled into the PMBB, including approximately 30% of participants of non-European ancestry, making it one of the most diverse medical biobanks. There is a median of seven years of longitudinal data in the EHR available on participants, who also consent to permission to recontact. Herein, we describe the operations and infrastructure of the PMBB, summarize the phenotypic architecture of the enrolled participants, and use body mass index (BMI) as a proof-of-concept quantitative phenotype for PheWAS, LabWAS, and GWAS. The major representation of African-American participants in the PMBB addresses the essential need to expand the diversity in genetic and translational research. There is a critical need for a "medical biobank consortium" to facilitate replication, increase power for rare phenotypes and variants, and promote harmonized collaboration to optimize the potential for biological discovery and precision medicine.


Related Papers

No related papers found

Powered by citation graph analysis